Mode
Text Size
Log in / Sign up

Review of BRIDGE model for predicting lipid-lowering therapy adherence trajectoriesNew tool predicts why patients stop heart meds and how to fix it

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider the BRIDGE model’s trajectory predictions to guide targeted adherence interventions, but recognize the need for external validation.

This review describes the development of the BRIDGE model, a barrier-informed Bayesian Risk prediction model designed to forecast adherence trajectories for lipid-lowering therapy among patients in primary care. The model was compared against machine learning methods including random forest and XGBoost. The primary outcome was adherence trajectories, with secondary outcomes focusing on model performance metrics.

The BRIDGE model achieved a macro AUROC of 0.809 (95% CI 0.806 to 0.813). Comparative performance showed random forest at 0.815 (95% CI 0.812 to 0.819) and XGBoost at 0.821 (95% CI 0.818 to 0.824). Calibration, measured by Brier score, was superior for BRIDGE (0.530) versus random forest (0.545). The use of barrier-informed priors improved accuracy by 3.5% and calibration by 5.5%. Model stability was high, with an SD of 0.003 across training runs.

The model identified four distinct adherence trajectories: early discontinuation (40.5%), rapid decline (28.8%), gradual decline (10.4%), and persistent adherence (20.2%). The authors propose that these trajectories could inform mechanism-specific interventions at the point of prescribing.

Key limitations include the lack of reported follow-up duration, sample size, and external validation. The findings are based on model development and performance metrics, not clinical outcomes. Practice relevance is limited to supporting targeted, mechanism-informed interventions, pending further validation.

Imagine you have a serious heart condition. You take a daily pill to keep your heart safe. But one day, you skip a dose. Then another. Soon, you are not taking the medicine at all. This happens to half of all patients with heart disease. It is a silent crisis that leads to heart attacks and death.

Doctors have tried hard to solve this problem. They tell patients to take their pills. They remind them to refill prescriptions. But these efforts often fail. Patients stop taking their medicine for many reasons. Some feel fine and think they do not need the drug. Others have too many pills to remember. Some simply cannot afford the cost.

But here is the twist. Current methods only look at a snapshot in time. They tell us if a patient took their pills last month. They do not explain the story behind the missed doses. They miss the dynamic patterns of adherence over time.

A New Way to See the Problem

Researchers have built a new digital tool called BRIDGE. It stands for Barrier-Informed Risk prediction for risk IDentification, trajectory Grouping, and profiling. Think of it as a smart detective for heart medicine habits.

This tool uses a special kind of math called Bayesian modeling. It does not just guess. It listens to the patient. It takes into account the barriers a patient faces. These barriers might be fear, cost, or confusion about the drug. By combining these patient stories with medical records, the model sees the whole picture.

Imagine a factory assembly line. Each worker adds a part to a product. In our body, different parts of the brain and body work together to make us take our medicine. Sometimes, a "traffic jam" blocks this process.

The BRIDGE model finds these traffic jams. It looks for specific reasons why a person might stop. For example, it might see that a patient feels no pain and decides the drug is unnecessary. Or it might see that a patient is taking ten different pills and feels overwhelmed.

The model creates a map of these journeys. It shows four distinct paths patients can take. One path is a slow decline where patients slowly stop because they have too many drugs. Another path is a fast drop because the medicine makes them feel sick. A third path is stopping early because patients think they are not at risk. The fourth path is staying on track.

The researchers tested this new tool on real data. They compared it to other smart computer programs used in medicine. The new tool performed just as well as the best ones. It correctly predicted which patients would struggle to stay on their medicine.

More importantly, it was very accurate. When the model said a patient was likely to stop, it was right most of the time. It also explained why the patient might stop. This is huge for doctors. Instead of guessing, they can see the specific reason.

There is a catch

This does not mean the tool is available in your doctor's office today.

The study was done on data from the past. It proved the math works. But getting this into real clinics takes time. Doctors need to learn how to use it. They need to enter patient stories into the system. It requires a change in how we think about prescribing.

If you take heart medicine, know that your reasons for stopping matter. Doctors want to understand your barriers. If you feel sick, if you are confused, or if you are worried about cost, tell your doctor.

This new approach gives doctors a way to listen better. It turns a vague problem into a specific plan. If the model finds you are struggling because of cost, the doctor can look for cheaper options. If you feel fine, the doctor can explain the hidden risks.

This is an early step. The study was published in a pre-print journal. It has not been fully reviewed by the big medical societies yet. More testing is needed to make sure it works for everyone.

We need to see if this tool helps real patients stay healthy. We need to see if it saves lives. The goal is simple. We want everyone to take their medicine safely. We want to stop the silent crisis of non-adherence.

The future of heart care is here. It listens to the patient. It understands the human side of taking pills. It turns data into a conversation. This is how we win the fight against heart disease.

Study Details

EvidenceLevel 5
PublishedApr 2026
View Original Abstract ↓
Background: Non-adherence to lipid-lowering therapy (LLT) affects up to half of patients and contributes substantially to preventable cardiovascular morbidity and mortality. Existing measures, such as the proportion of days covered, provide cross-sectional summaries but fail to capture the dynamic patterns of adherence over time. Although group-based trajectory modelling identifies distinct longitudinal adherence patterns, no approach currently predicts trajectory membership prospectively while incorporating patient-reported barriers. We developed BRIDGE, a barrier-informed Bayesian model to predict adherence trajectories and identify their underlying drivers. Methods: BRIDGE incorporates patient-reported barriers as structured prior information within a Bayesian framework for adherence-trajectory prediction. The model was designed not only to estimate which patients are likely to follow different adherence trajectories, but also to generate clinically interpretable probability estimates that help explain why those trajectories may arise and what modifiable factors may be most relevant for intervention. Results: BRIDGE achieved a macro AUROC of 0.809 (95% CI 0.806 to 0.813), comparable to random forest (0.815 (95% CI 0.812 to 0.819)) and XGBoost (0.821 (95% CI 0.818 to 0.824)), two widely used machine-learning benchmarks for structured clinical prediction. Calibration was superior to random forest (Brier score 0.530 vs 0.545; ), and performance was stable across six independent training runs (AUROC SD = 0.003). Incorporating barrier-informed priors improved accuracy by 3.5% and calibration by 5.5% compared to flat priors, showing that incorporation of patient-reported barriers added value beyond electronic medical record data alone. Four clinically distinct adherence trajectories were identified: gradual decline associated with treatment deprioritisation amid polypharmacy (10.4%), early discontinuation linked to asymptomatic risk dismissal (40.5%), rapid decline associated with intolerance (28.8%), and persistent adherence (20.2%). Counterfactual analysis identified trajectory-specific intervention levers. Conclusions: BRIDGE provides accurate and well-calibrated prediction of adherence trajectories while offering clinically actionable insights into their underlying drivers. By integrating patient-reported barriers with routine clinical data, the model supports targeted, mechanism-informed interventions at the point of prescribing to improve adherence to cardioprotective therapies. Funding MRFF CVD Mission Grant 2017451
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.